Pulmonary

Physician Registration

Interested in Conducting a
Clinical Research Trial?

Click Here for
Physician Partner Registration

Pulmonary

Current Clinical Trials in Asthma, Chronic Obstructive Pulmonary Disease(COPD), Cystic Fibrosis, Pulmonary Arterial Hypertension (PAH) and Idiopathic Pulmonary Fibrosis

An Observational Prospective Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants (32 to 35 Week Gestational Age) - Outcomes and Risk Tracking Study (The Report Study)

This is an observational, prospective study of preterm infants 32 to 35 wGA. Subjects will be screened and entered into the study during their earliest pediatric outpatient visit (routine well-baby visit or unscheduled sick visit), from 01Sep2009 through 31Jan2010 for Season 1, and from 01Sep2010 through 31Jan2011 for Season 2. All subjects will be followed up to the end of their first RSV season (31May). Interval (between-visit) RSV infections, hospitalizations, ED visits, and outpatient LRIs will be assessed during each follow-up visit between the Initial Visit and 31May. When an interval event is reported, medical records/charts will be obtained by the investigator to collect all study-pertinent information, including any RSV testing and results.

Chronic Obstructive Pulmanary Disease (COPD) Post-hospitalization Study

This trial is a randomized, double-blind, parallel-group, multicenter study to be conducted in the United States. The purpose of the study is to evaluate the rate of exacerbations of chronic obstructive pulmonary disease (COPD) following hospital discharge for an acute exacerbation of COPD, in patients receiving either fluticasone propionate/salmeterol combination product 250/50mcg BID or salmeterol 50mcg BID via DISKUS™ over 29 weeks. The study population will include patients hospitalized for an acute exacerbation of COPD

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period. This study is evaluating both children 12- 17 years of age and adults.

One Year Study – Study No. AC-063A406

One Year Study – Study No. AC-063A406

A multicenter, retrospective study of patients with pulmonary arterial hypertension receiving inhaled iloprost for ≥ year

A Study of Xolair in Subjects With Moderate to Severe Persistent Asthma (EXTRA)

This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy to high-dose ICS+LABA for the treatment of subjects aged 12-75 years old diagnosed with moderate to severe asthma who are inadequately controlled with high-dose ICS+LABA.

Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients

To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.

Aztreonam for Inhalation Solution (AZLI) vs Tobramycin Inhalation Solution (TOBI®) in Patients With CF & P. Aeruginosa

The purpose of this study is to assess the comparative safety and effectiveness of Aztreonam for Inhalation Solution versus Tobramycin Nebuliser Solution in adult and pediatric patients with CF and pulmonary Pseudomonas aeruginosa (PA) infection.

AMBITION: A Randomised, Multicenter Study of First-Line

A randomised multicenter study comparing the effect on time to

clinical failure of initial combination therapy (ambrisentan and

tadalafil) and initial monotherapy (ambrisentan or tadalafil) in

subjects with pulmonary arterial hypertension.

A Comparison of SYMBICORT pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST2)

This study will assess efficacy and safety of indacaterol (150 µg once daily [o.d.]) when combined with tiotropium (18 µg o.d.) versus tiotropium (18 µg o.d.) treatment alone in patients with chronic obstructive pulmonary disease (COPD)

More Articles...